ArticleJTCVS techniques2026
Feasibility of tissue-engineered tracheal and bronchial reconstruction using an in vivo bioreactor technique.
Article in JTCVS techniques, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Reconstruction of long-segment airway defects remains challenging because previous attempts at tissue-engineered airway (TEA) replacement have failed to provide long-term follow-up data. We report the feasibility of a novel in vivo bioreactor technique for TEA reconstruction to correct long-segment tracheal and bronchial defects. Methods: The outcomes of 7 patients with end-stage tracheal lesions or proximal lung tumors requiring pneumonectomy who underwent radical lesion resection using a standard surgical technique, followed by TEA reconstruction with an in vivo bioreactor technique were retrospectively reviewed. An intramural nitinol stent was inserted between 2 layers of an acellular porcine dermal matrix, with 2 Port-a-Cath (Smiths Medical) catheters connected to a portable peristaltic pump. The TEA was continuously perfused with an antibiotic solution, and peripheral total nucleated cells were harvested and seeded into the implanted TEA substitute twice per week for 2 months. Results: The 7 patients (mean age, 49 years; range, 33-67 years; 4 men) underwent either tracheal (n = 5) or bronchial (n = 2) reconstruction. Two of the 7 patients died within 1 year due to fistula formation between the trachea and brachiocephalic artery. One other major morbidity event (upper anastomosis leakage) was resolved with a longer membrane stent. Three patients died due to tumor relapse (median follow-up, 2 years), whereas 2 patients are still alive (follow-up, 6.5 years). Two patients underwent biopsy-confirmed TEA re-epithelialization. Conclusions: The findings of this uncontrolled study suggest that TEA using an in vivo bioreactor technique is feasible for long-segment trachea and bronchial reconstruction. Further studies are needed to evaluate efficacy and safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.